切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2009, Vol. 03 ›› Issue (06) : 633 -641. doi: 10.3877/cma.j.issn.1674-0807.2009.06.007

实验研究

浸润性T淋巴细胞及Th细胞因子在不同类型乳腺癌中的表达
徐新生1, 郭晓静1, 刘芳芳1, 李伟东1, 刘冰冰1, 谷峰1, 郎荣刚1, 范宇1, 付丽1,()   
  1. 1.300060 天津,天津医科大学附属肿瘤医院乳腺病理科教育部乳腺癌研究重点实验室
  • 收稿日期:2009-06-19 出版日期:2009-12-01
  • 通信作者: 付丽
  • 基金资助:
    国家自然科学基金资助项目(30600225)教育部长江学者奖励计划乳腺癌创新团队(IRT0743)国家“863”计划项目(2006AA02A249)国家“973”计划项目(2009CB521700)

Expression of infiltrating T lymphocytes and T helper cytokines in different types of breast cancer

Xin-sheng XU1, Xiao-jing GUO1, Fang-fang LIU1, Wei-dong LI1, Bing-bing LIU1, Feng GU1, Rong-gang LANG1, Yu FAN1, Li FU,1()   

  1. 1.Department of Breast Cancer Pathology,Cancer Institute and Hospital,Tianjin Medical University;State Key Laboratory of Breast Cancer Research,Tianjin 300060,China
  • Received:2009-06-19 Published:2009-12-01
  • Corresponding author: Li FU
引用本文:

徐新生, 郭晓静, 刘芳芳, 李伟东, 刘冰冰, 谷峰, 郎荣刚, 范宇, 付丽. 浸润性T淋巴细胞及Th细胞因子在不同类型乳腺癌中的表达[J/OL]. 中华乳腺病杂志(电子版), 2009, 03(06): 633-641.

Xin-sheng XU, Xiao-jing GUO, Fang-fang LIU, Wei-dong LI, Bing-bing LIU, Feng GU, Rong-gang LANG, Yu FAN, Li FU. Expression of infiltrating T lymphocytes and T helper cytokines in different types of breast cancer[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2009, 03(06): 633-641.

目的

研究浸润性T淋巴细胞和Th细胞因子在不同类型乳腺癌中表达的意义。

方法

利用免疫组织化学链霉亲和素生物素法(labelled streptavidin-biotin method,LSAB)方法检测61例浸润性微乳头状癌(invasive micropapillary carcinoma,IMPC)、71例浸润性导管癌(invasive ductal carcinoma,IDC)和27例髓样癌(medullary carcinoma,MC)3种乳腺癌中浸润T淋巴细胞亚群分布以及Th细胞因子的表达。T淋巴细胞组间比较采用Kruskal-Wallis Test,组内比较采用Wilcoxon Signed Ranks Test;组间Th细胞因子的比较采用χ2检验。

结果

CD3、CD8和CD4均表达于淋巴细胞胞膜。CD3+T细胞在3组间差异无统计学意义(P=0.735)。CD8+T和CD4+T细胞在3组间差异均有统计学意义(P=0.000,P=0.012)。Th细胞因子主要表达于肿瘤细胞和淋巴细胞的胞质。IL-2表达在IMPC组最低(25/61,41.0%),其次是IDC组(33/71,46.5%),最高是MC组(20/27,74.1%),3组间差异有统计学意义(P=0.014);IFN-γ的表达类似于IL-2,IMPC组最低(39/61,63.9%),其次是IDC组(57/71,80.3%),最高是MC组(24/27,88.9%),3组间差异有统计学意义(P=0.019);IL-4的表达在IDC组最高(42/71,59.2%),其次是IMPC组(19/61,31.1%),最低是MC组(5/27,18.5%),3组间差异有统计学意义(P=0.000);IL-10的阳性率在IMPC组是87.8%(47/61),在IDC组是87.3%(62/71),在MC组是88.9%(24/27),3组间差异无统计学意义(P>0.050)。

结论

浸润性T淋巴细胞和Th细胞因子在不同类型乳腺癌中表达不同。

Objective

To study the expression of tumor-infiltrating lymphocytes(TILs)and T helper cytokines in invasive micropapillary carcinoma(IMPC),invasive ductal carcinoma(IDC)and medullary carcinoma(MC)of the breast.

Methods

Three T-cell markers including pan-T cell marker(CD3),T-helper cell marker(CD4),cytotoxic T cell marker(CD8),and four T-helper cytokines including interleukin-2(IL-2),interferon-gamma(IFNγ),interleukin-4(IL-4),and interleukin-10(IL-10)were tested immunohistochemically in the three groups,(IMPC n=61,IDC n=71,and MC n=27)on formalin-fixed,paraffin embedded tumors.Kruskal-Wallis Test and Wilcoxon Signed Ranks Test were used for analysis of TILs;chi-square test was used for analysis of T helper cytokines.

Results

Markers,CD3,CD4 and CD8,all expressed in the cell membrane of lymphocytes.There was no statistical difference in CD3+T cells number between the three groups(P=0.705);CD8+T cells and CD4+T cells were statistically different between the three groups(P=0.000,P=0.012).T helper cytokines expressed in cytoplasm of tumour cells and lymphocytes.The expression of IL-2 was the highest in the MC group(20/27,74.1%),followed by the IDC group(33/71,46.5%),and the lowest in the IMPC group(25/61,41.0%),there was a statistical difference between the three groups(P=0.014).The expression of IFN-γwas the highest in the MC group(24/27,88.9%)followed by the IDC group(57/71,80.3%),and the lowest in the IMPC group(39/61,63.9%),there was a statistical difference between the three groups(P=0.019).The positive expression of IL-4 was the highest in the IDC group(42/71,59.2%),followed by the IMPCgroup(19/61,31.1%)and the lowest in the MC group(5/27,18.5%),there was a statistical difference between the three groups(P=0.000).The positive rate of IL-10 expression was 87.8%(47/61)in the IMPC group,87.3%(62/71)in the IDC group,and 88.9%(24/27)in the MC group,with no statistical difference between the three groups.(P>0.050).

Conclusion

The expressions of infiltrating T lymphocytes and T helper cytokines were different in different types of breast carcinomas,which may be responsible for different biologic behavior.

表1 3组乳腺癌的临床病理学特征
图1 3种类型乳腺癌中的淋巴细胞的分布和表型(DAB染色 ×100) IMPC:浸润性微乳头状癌;MC:髓样癌;IDC:浸润性导管癌
表2 3组乳腺癌中浸润T淋巴细胞亚群的比较
图2 3种类型乳腺癌中Th细胞因子的表达(DAB染色 ×100) IMPC:浸润性微乳头状癌;MC:髓样癌;IDC:浸润性导管癌
表3 3组乳腺癌中Th细胞因子的比较
[1]
Tsuta K,Ishii G,Kim E,et al.Primary lung adenocarcinoma with massive lymphocyte infiltration.Am J Clin Pathol,2005,123:547-552.
[2]
Canna K,Mc Ardle P A,Mc Millan D C,et al.The relationship between tumour T-lymphocyte infiltration,the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer.Br J Cancer,2005,92:651-654.
[3]
Tavassoli F A,Devilee P.WHO classification of tumors:pathology,genetics,tumors of the breast and female genital organs.Lyon:IARC Press,2003:35-36.
[4]
Tresserra F,Grases P J,Fabregas R,et al.Invasive micropapillary carcinoma:distinct features of a poorly recognized variant of breast carcinoma.Eur J Gynaecol Oncol,1999,20:205-208.
[5]
Middleton L P,Tressera F,Sobel M E,et al.Infiltrating micropapillary carcinoma of the breast.Mod Pathol,1999,12:499-504.
[6]
Luna More S,Casquero S,Perez-Mellado A,et al.Importance of eatrogen receptor for the behavior of invasive micropapillary carcinoma of the breast:review of 68 cases with follow-up of 54 months.Pathol Res Pract,2000,196:35-39.
[7]
Luna More S,Gonzalez B,Acedo C,et al.Invasive micropapillary carcinoma of the breast:a new special type of invasive mammary carcinoma.Pathol Res Pract,1994,190:668-674.
[8]
Tsumagari K,Sakamoto G,Akiyama F,et al.The pathological diagnosis and clinical significance of invasive micropapillary carcinoma of the breast.Jpn J Breast Cancer,2001,16:441-447.
[9]
Nassar H,Wallis T,Andea A,et al.Clinicopathologic analysis of invasive micropapillary differenciation in breast carcinoma.Mod Pathol,2001,14:836-841.
[10]
陈凌,范宇,郎荣刚,等.伴有浸润性微乳头状癌结构乳腺癌的诊断和预后研究.中华病理学杂志,2007,36:228-231.
[11]
Guo X,Chen L,Lang R,et al.Invasive micropapillary carcinoma of the breast:association of pathologic features with lymph node metastasis.Am J Clin Pathol,2006,126:740-746.
[12]
Rapin V,Contesso G,Mouriesse H,et al.Medullary breast carcinoma:a reevaluation of 95 cases of breast cancer with inflammatory stroma.Cancer,1998,61:2503-2510.
[13]
Wargotz E S,Silverbreg S G.Medullary carcinoma of the breast:a clinicopathologic study with appraisal of current diagnostic criteria.Hum Pathol,1998,19:1340-1346.
[14]
Ridolfi R L,Rosen P P,Port A,et al.Medullary carcinoma of the breast:a clinicopathologic study with 10 year follow-up.Cancer,1997,40:1365-1385.
[15]
Coronella J A,Spier C,Welch M,et al.Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast.J Immunol,2002,169:1829-1836.
[16]
Nzula S,Going JJ,Stott D I.Antigen driven clonal proliferation,somatic hypermutation,and selection of B lymphocytes infiltrating human ductal breast carcinomas.Cancer Res,2003,63:3275-3280.
[17]
Guo X,Fan Y,Lang R,et al.Tumor infiltrating lymphocytes differ in invasive micropapillary carcinoma and medullary carcinoma of breast.Mod Pathol,2008,21:1101-1107.
[18]
Georgiannos S N,Renaut A,Goode A W,et al.The immunophenotype and activation status of the lymphocytic infiltrate in human breast cancers,the role of the major histocompatibility complex in cell-mediated immune mechanisms,and their association with prognostic indicators.Surgery,2003,134:827-834.
[19]
Marrogi A J,Munshi A,Merogi A J,et al.Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma.Int J Cancer,1997,74:492-501.
[20]
Macchetti A H,Marana H R,Silva J S,et al.Tumor-infiltrating CD4+T lymphocytes in early breast cancer reflect lymph node involvement.Clinics,2006,61:203-208.
[21]
Leong P P,Mohammad R,Ibrahim N,et al.Phenotyping of lymphocytes expressing regulatory and effector markers in infiltrating ductal carcinoma of the breast.Immunol Lett,2006,102:229-236.
[22]
Shimizu M,Saitoh Y,Itoh H,et al.Immunohistochemical staining of Ha2ras oncogene product in normal,benign,and malignant human pancreatic tissues.Human Pathol,1990,21:607-612.
[23]
Abbas A K,Murphy K M,Sher A.Functional diversity of helper T lymphocytes.Nature,1996,383:787-793.
[24]
Romagnani S.Lymphokine production by human T cells in disease states.Annu Rev lmmunol,1994,12:227-257.
[25]
Lauerova L,Dusek L,Simickova M,et al.Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.Neoplasma,2002,49:159-166.
[26]
Agarwal A,Ran i M,Saha G K,et al.Disregulated expression of the Th2 cytokine gene in patients with intraoral squamous cell carcinoma.Immunol Invest,2003,32:17-30.
[27]
Todaro M,Zerilli M,RicciVitiani L.Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells.Cancer Res,2006,66:1491-1499.
[28]
Abehsira Amar O,Gibert M,Joliy M,et al.IL-4 plays a dominant role in the differential development of Tho into Th1 and Th2 cells.J Immunol.1992,148:3820-3829.
[29]
Hosken N A,Shibuya K,Heath A W,et al.The effect of antigen dose on CD4+T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model.J Exp Med,1995,182:1579-1584.
[30]
Pfeiffer C,Stein S,Southwood S,et al.Altered peptide ligands can control CD4 T lymphocyte differentiation in vivo.J Exp Med,1995,181:1569-1574.
[31]
Constant S,Pfeiffer C,T.Woodard A,et al.Extent of T cell receptor ligation can determine the function differentiation of naive CD4+T cells.J Exp Med,1995,182:1591-1596.
[32]
安云庆,高晓明.医学免疫学.北京:北京大学医学出版社,2004:185-187.
[33]
Reinhard G,Noll A,Schlebusch H,et al.Shifts in the Th1/Th2 balance during human pregnancy correlate with apoptotic changes.Biochem Biophys Res Commun,1998,245:933-938.
[1] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[2] 周荷妹, 金杰, 叶建东, 夏之一, 王进进, 丁宁. 罕见成人肋骨郎格汉斯细胞组织细胞增生症被误诊为乳腺癌术后骨转移一例[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 380-383.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 邱琳, 刘锦辉, 组木热提·吐尔洪, 马悦心, 冷晓玲. 超声影像组学对致密型乳腺背景中非肿块型乳腺癌的诊断价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 353-360.
[7] 程燕妮, 樊菁, 肖瑶, 舒瑞, 明昊, 党晓智, 宋宏萍. 乳腺组织定位标记夹的应用与进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 361-365.
[8] 涂盛楠, 胡芬, 张娟, 蔡海峰, 杨俊泉. 天然植物提取物在乳腺癌治疗中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 366-370.
[9] 朱文婷, 顾鹏, 孙星. 非酒精性脂肪性肝病对乳腺癌发生发展及治疗的影响[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 371-375.
[10] 葛睿, 陈飞, 李杰, 李娟娟, 陈涵. 多基因检测在早期乳腺癌辅助治疗中的应用价值[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(05): 257-263.
[11] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[12] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[13] 张志兆, 王睿, 郜苹苹, 王成方, 王成, 齐晓伟. DNMT3B与乳腺癌预后的关系及其生物学机制[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 624-629.
[14] 王玲艳, 高春晖, 冯雪园, 崔鑫淼, 刘欢, 赵文明, 张金库. 循环肿瘤细胞在乳腺癌新辅助及术后辅助治疗中的应用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 630-633.
[15] 赵林娟, 吕婕, 王文胜, 马德茂, 侯涛. 超声引导下染色剂标记切缘的梭柱型和圆柱型保乳区段切除术的效果研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 634-637.
阅读次数
全文


摘要